🇺🇸 FDA

Company profile · Sponsor

Regeneron

Regeneron Ireland Designated Activity Company (DAC)

RGBP · NYSE pharma LA MESA, CA, IE
Pipeline
10
Drugs
12
Patents
8

Quick answer

Regeneron (RGBP) is a pharma company. headquartered in LA MESA, CA, IE. listed on NYSE. NovaPharmaNews links 10 pipeline programs, 12 drugs, and 8 patents to this profile..

Company facts

Ticker RGBP
Exchange NYSE
Company type pharma
Headquarters LA MESA, CA, IE
SEC CIK 0001589150

Pipeline (10)

Search pipeline →

  1. Autologous (self) mononuclear cells derived from umbilical cord blood

    Regeneron

    Hypoplastic Left Heart Syndrome

    phase 2 mab active

    1 trial

  2. Autologous Bone Marrow-derived Mononuclear Cells

    Regeneron

    Congenital Heart Disease

    phase 1 mab completed

    1 trial

  3. Autologous mononuclear cells

    Regeneron

    Congenital Heart Disease, SRV Dependent

    phase 1 mab active

    1 trial

  4. Extracellular Vesicles from Mesenchymal Stem Cells

    Regeneron

    COVID-19 Pneumonia

    phase 1 mab active

    1 trial

  5. MSC-derived exosomes

    Regeneron

    Long COVID-19 Syndrome

    phase 1 mab active

    1 trial

  6. autologous cell-based delivery

    Regeneron

    Hypoplastic Left Heart Syndrome

    phase 1 mab completed

    1 trial

  7. Cellular Matrix / A-CP-HA Kit

    Regeneron

    Genitourinary Syndrome of Menopause

    approved small molecule active

    1 trial

  8. hyaluronic Acid + platelet-rich plasma

    Regeneron

    Knee Osteoarthritis

    approved small molecule completed

    1 trial

  9. Placebo

    Regeneron

    Knee Osteoarthritis

    small molecule active

    1 trial

  10. Regen Matrix-PRP-XLHA

    Regeneron

    Knee Osteoarthritis

    other active

    1 trial

Drugs (12)

Search drugs →

  1. acetylcysteine

    ACETYLCYSTEINE

    ORAL approved

  2. adenosine

    ADENOSINE

    INJECTION approved

  3. aminophylline

    AMINOPHYLLINE

    RECTAL approved

  4. betamethasone acetate

    BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

    INJECTION approved

  5. calcium chloride

    DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER

    IRRIGATION approved

  6. chlorothiazide sodium

    CHLOROTHIAZIDE SODIUM

    INJECTION approved

  7. clonidine hydrochloride

    CLONIDINE HYDROCHLORIDE

    INJECTION approved

  8. cupric sulfate

    CUPRIC SULFATE

    INJECTION approved

  9. cyanocobalamin

    CYANOCOBALAMIN

    N/A approved

  10. dactinomycin

    DACTINOMYCIN

    INJECTION approved

  11. desmopressin acetate

    MINIRIN

    ORAL approved

  12. dexmedetomidine hydrochloride

    DEXMEDETOMIDINE HYDROCHLORIDE

    BUCCAL, SUBLINGUAL approved

Patents (8)

Search patents →

  1. US 12428416

    ERK inhibitors and uses thereof

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12428463

    Chimeric antigen receptors targeting abnormal glycobiology

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12427155

    Treatment for tau-related diseases

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12427197

    Methods of producing cobalt nanoparticles and hollow metal nanospheres

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12427151

    Compositions and method of treating cancer

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12428455

    Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12427148

    Cancer treatment targeted to tumor adaptive responses to protein synthesis stress

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12428489

    Human PD-L2 antibodies and methods of use therefor

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Regeneron?

Regeneron (RGBP) is a pharma company. headquartered in LA MESA, CA, IE. listed on NYSE. NovaPharmaNews links 10 pipeline programs, 12 drugs, and 8 patents to this profile..

What pipeline programs does Regeneron sponsor?

We track 10 ClinicalTrials.gov-linked programs for Regeneron, including Autologous (self) mononuclear cells derived from umbilical cord blood and 9 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Regeneron company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.